Refine
Year of publication
Has Fulltext
- yes (33)
Is part of the Bibliography
- no (33)
Keywords
- ADHD (1)
- Biotin (1)
- CNVs (1)
- Esters (1)
- Eukaryota (1)
- GWAS (1)
- Internal ribosome entry site (1)
- Luciferase (1)
- PARK2 (1)
- Phosphorylation (1)
The first measurements of dielectron production at midrapidity (|ηc|<0.8) in proton-proton and proton-lead collisions at sNN−−−√ = 5.02 TeV at the LHC are presented. The dielectron cross section is measured with the ALICE detector as a function of the invariant mass mee and the pair transverse momentum pT,ee in the ranges mee < 3.5 GeV/c2 and pT,ee < 8.0 GeV/c2, in both collision systems. In proton-proton collisions, the charm and beauty cross sections are determined at midrapidity from a fit to the data with two different event generators. This complements the existing dielectron measurements performed at s√ = 7 and 13 TeV. The slope of the s√ dependence of the three measurements is described by FONLL calculations. The dielectron cross section measured in proton-lead collisions is in agreement, within the current precision, with the expected dielectron production without any nuclear matter effects for e+e− pairs from open heavy-flavor hadron decays. For the first time at LHC energies, the dielectron production in proton-lead and proton-proton collisions are directly compared at the same sNN−−−√ via the dielectron nuclear modification factor RpPb. The measurements are compared to model calculations including cold nuclear matter effects, or additional sources of dielectrons from thermal radiation.
The first measurements of dielectron production at midrapidity (|ηc|<0.8) in proton-proton and proton-lead collisions at sNN−−−√ = 5.02 TeV at the LHC are presented. The dielectron cross section is measured with the ALICE detector as a function of the invariant mass mT,ee and the pair transverse momentum pT,ee in the ranges mT,ee < 3.5 GeV/c2 and mT,ee < 8.0 GeV/c2, in both collision systems. In proton-proton collisions, the charm and beauty cross sections are determined at midrapidity from a fit to the data with two different event generators. This complements the existing dielectron measurements performed at s√ = 7 and 13 TeV. The slope of the s√ dependence of the three measurements is described by FONLL calculations. The dielectron cross section measured in proton-lead collisions is in agreement, within the current precision, with the expected dielectron production without any nuclear matter effects for e+e− pairs from open heavy-flavor hadron decays. For the first time at LHC energies, the dielectron production in proton-lead and proton-proton collisions are directly compared at the same sNN−−−√ via the dielectron nuclear modification factor RpPb. The measurements are compared to model calculations including cold nuclear matter effects, or additional sources of dielectrons from thermal radiation.
The first measurements of dielectron production at midrapidity (|ηc|<0.8) in proton-proton and proton-lead collisions at sNN−−−√ = 5.02 TeV at the LHC are presented. The dielectron cross section is measured with the ALICE detector as a function of the invariant mass mee and the pair transverse momentum pT,ee in the ranges mee < 3.5 GeV/c2 and pT,ee < 8.0 GeV/c2, in both collision systems. In proton-proton collisions, the charm and beauty cross sections are determined at midrapidity from a fit to the data with two different event generators. This complements the existing dielectron measurements performed at s√ = 7 and 13 TeV. The slope of the s√ dependence of the three measurements is described by FONLL calculations. The dielectron cross section measured in proton-lead collisions is in agreement, within the current precision, with the expected dielectron production without any nuclear matter effects for e+e− pairs from open heavy-flavor hadron decays. For the first time at LHC energies, the dielectron production in proton-lead and proton-proton collisions are directly compared at the same sNN−−−√ via the dielectron nuclear modification factor RpPb. The measurements are compared to model calculations including cold nuclear matter effects, or additional sources of dielectrons from thermal radiation.
The identification of inhibitors of eukaryotic protein biosynthesis, which are targeting single translation factors, is highly demanded. Here we report on a small molecule inhibitor, gephyronic acid, isolated from the myxobacterium Archangium gephyra that inhibits growth of transformed mammalian cell lines in the nM range. In direct comparison, primary human fibroblasts were shown to be less sensitive to toxic effects of gephyronic acid than cancer-derived cells. Gephyronic acid is targeting the protein translation system. Experiments with IRES dual luciferase reporter assays identified it as an inhibitor of the translation initiation. DARTs approaches, co-localization studies and pull-down assays indicate that the binding partner could be the eukaryotic initiation factor 2 subunit alpha (eIF2α). Gephyronic acid seems to have a different mode of action than the structurally related polyketides tedanolide, myriaporone, and pederin and is a valuable tool for investigating the eukaryotic translation system. Because cancer derived cells were found to be especially sensitive, gephyronic acid could potentially find use as a drug candidate.
Background: Real‐world evidence is sparse on the benefits of allergen immunotherapy [AIT; subcutaneous/sublingual immunotherapy (SCIT/SLIT)], the only disease‐modifying intervention for allergic rhinitis (AR) with long‐term efficacy. This real‐life study evaluated the effect of six AITs (native pollen SLIT/SCIT, four allergoid SCITs) vs symptomatic medication use, on AR symptoms and asthma symptoms/onset, in patients with birch pollen‐associated AR and/or asthma.
Methods: In this retrospective cohort analysis of a German longitudinal prescription database, AIT patients received ≥2 successive seasonal treatment cycles; non‐AIT patients had ≥3 AR prescriptions in three seasons or previous month. Patients were matched for: index year, age, gender, main indication at index, number of seasonal cycles within treatment period, baseline AR/asthma treatment prescriptions. Multiple regression analysis compared prescription data in AIT and non‐AIT groups as proxy for clinical status/disease progression.
Results: Up to 6 years of follow‐up, significantly more AIT (65.4%) vs non‐AIT (47.4%) patients were AR medication‐free; odds ratio (OR) [95% confidence interval (CI)]: 0.51 [(0.48‐0.54); P < 0.001] (28.6% covariate‐adjusted reduction vs non‐AIT; P < 0.001), and significantly more AIT (49.1%) vs non‐AIT (35.1%) patients were asthma medication‐free [OR (95% CI): 0.59 (0.55‐0.65); P < 0.001] (32% reduction vs non‐AIT; P < 0.001), or reduced existing asthma medication use (32% covariate‐adjusted reduction vs non‐AIT; P < 0.001). During treatment, new‐onset asthma risk was significantly reduced in the AIT vs non‐AIT group (OR: 0.83; P = 0.001).
Conclusions: Birch pollen AIT demonstrated real‐world benefits up to 6 years post‐treatment cessation through significantly reduced AR and asthma medication intake, and significantly decreased risk of new‐onset asthma medication use on‐treatment.
Die Hessische Landesforstverwaltung hat mit Erlaß vom 14.4.1983 - Az.: III B 3 - 3378 - F 36 - die Verbandsbeteiligung gemäß § 29 Bundesnaturschutzgesetz freiwillig auf die Mitwirkung im Forsteinrichtungsverfahren erweitert. Damit haben erstmalig in der Bundesrepublik Deutschland Naturschutzverbände auch Gelegenheit, direkt bei dieser wichtigen forstlichen Planung aktiv mitzuwirken.
Es ist das Anliegen der Naturschutzverbände, auch bei der Bewirtschaftung der Wälder ökologische Wertvorstellungen zu verankern. Zwar gilt Wald als besonders naturnahe Form von Landbewirtschaftung, dennoch wissen wir, daß auch jede noch so naturnahe Bewirtschaftung von Waldbeständen mit einem erheblichen Artenverlust verbunden ist.
Darüber hinaus möchten die Naturschutzverbände alle Bemühungen unterstützen, den Laubwaldanteil in hessischen Wäldern zu erhalten und langfristig wieder zu erhöhen, denn die ursprünglichen, natürlichen Wälder Hessens sind nun einmal - auf ganz wenigen Standorten in Südhessen ausgenommen - reine Laubwälder, die den typischen, ursprünglichen Lebensraum für fast alle bei uns heimischen Waldpflanzen und -tiere darstellen. Die Verbände verkennen dabei nicht, daß auf vielen Standorten die nicht heimischen Nadelbaumarten einen wichtigen Beitrag zur Versorgung mit einem nachwachsenden, unentbehrlichen Rohstoff darstellen. Für einen ökologisch orientierten Waldbau ist aber wesentlich, daß
- die noch vorhandenen Laubwaldflächen als solche erhalten bleiben,
- keine Nadelwald-Reinbestände mehr begründet werden,
- die naturnahen Laubwaldreste im Rahmen des bundesweiten Naturwaldreservate-Programms gesichert werden,
- von der Kahlschlagwirtschaft Abstand genommen und naturnahe Waldbewirtschaftung verbindlich gemacht wird und
- der Totholzanteil im Laubwald landesweit deutlich erhöht wird.
In diesem Sinne verstehen die Verfasser diesen Leitfaden, der für mehr "Naturschutz im Walde" und für eine konstruktive Zusammenarbeit zwischen Forstleuten und Naturschützern in Hessen führen sollte.
Background: Aside from the fully licensed herbal medicines there are products on the European pharmaceutical market which are registered by virtue of their longstanding traditional use. The normal registration procedure does not apply to them because presently they do not meet the legal requirements for a full license as set out in the relevant European Union Directive. One of these requirements, “proof of tradition”, has so far been dealt with in different ways and fails to meet the criteria of good practice.
Method: This analysis is based on a selective literature search in PubMed and in databases of medical and pharmaceutical history, interviews with licensing experts, a consensus meeting attended by researchers with a background in general medicine, phytotherapy, medical and pharmaceutical history, biometry, ethnopharmacology, pharmacognosy and the pharmaceutical industry.
Results and discussion: The 2004 EU Directive, which governs the registration of Traditional Herbal Medicinal Products and demands proof of tradition, is a regulatory construct and, above all, the outcome of a political process that has ended in a pragmatic compromise. The concept of tradition applied in the Directive does not sufficiently reflect the semantic breadth of the term. The only condition defined is that a specific commercial preparation needs to have been on the market for 30 years (15 of them inside the EU). Such an approach does not make full scientific use of the evidence available because the information excerpted from historical sources, if adequately processed, may yield valuable insights. This applies to indications, modes of application, efficacy and product safety (innocuousness). Such criteria should enter in full into the benefit-risk-analysis of applied preparations, in the registration process as well as in the therapeutic practice.
Conclusion: When registering Traditional Herbal Medicinal Products the criterion of evidence-based medicine will only be met if all the facts available are assessed and evaluated, over and above the formally stipulated regulatory provisions (30 years, product reference). To this end, the scientific methods (from among the natural, life or cultural sciences), which are recognized as authoritative in each case, must be applied.
Two-particle correlation functions of negative hadrons over wide phase space, and transverse mass spectra of negative hadrons and deuterons near mid-rapidity have been measured in central Pb+Pb collisions at 158 GeV per nucleon by the NA49 experiment at the CERN SPS. A novel Coulomb correction procedure for the negative two-particle correlations is employed making use of the measured oppositely charged particle correlation. Within an expanding source scenario these results are used to extract the dynamic characteristics of the hadronic source, resolving the ambiguities between the temperature and transverse expansion velocity of the source, that are unavoidable when single and two particle spectra are analysed separately. The source shape, the total duration of the source expansion, the duration of particle emission, the freeze-out temperature and the longitudinal and transverse expansion velocities are deduced.
We report measurements of Xi and Xi-bar hyperon absolute yields as a function of rapidity in 158 GeV/c Pb+Pb collisions. At midrapidity, dN/dy = 2.29 +/- 0.12 for Xi, and 0.52 +/- 0.05 for Xi-bar, leading to the ratio of Xi-bar/Xi = 0.23 +/- 0.03. Inverse slope parameters fitted to the measured transverse mass spectra are of the order of 300 MeV near mid-rapidity. The estimated total yield of Xi particles in Pb+Pb central interactions amounts to 7.4 +/- 1.0 per collision. Comparison to Xi production in properly scaled p+p reactions at the same energy reveals a dramatic enhancement (about one order of magnitude) of Xi production in Pb+Pb central collisions over elementary hadron interactions.